Why Exhibit at CPhI Japan 2016?
Present your company to a high quality audience
CPhI Japan with its co-located events - P-MEC for machinery & equipment, ICSE for outsourcing solutions, BioPh for bio-technology and InnoPack for Drug Packaging and Delivery Technology - is the industry's premier business platform where over 16,000 pharma professionals gather.
Key benefits to book a stand at CPhI Japan 2016:
Meet your clients:
Doing business in Japan as a foreigner requires close business connections with your Japanese partners. How these are maintained can make all the difference when it comes to the success of an ongoing business. CPhI Japan offers the perfect platform to reaffirm established connections with your Japanese customers.
Benefit from new legislation:
Once known as very difficult to penetrate, the Japanese pharmaceutical market is now much more accessible to foreign investment due to changes in legislation that reflect new demographics and approaches to market dynamics. The new legislation favours businesses that focus on innovation, generics manufacturing and support services industries such as CMOs and CROs. Take advantage of these ongoing changes and tap into this market worth over $89 billion per year.
Showcase your products and services:
CPhI Japan hosts over 16,000 senior-level decision makers looking to buy. Having your products and services present for visitors to see first-hand allows for much more convincing face-to-face engagement through meetings and presentations at your stand or other event happenings.
Now is the time to enter the market:
Negotiations for the Free Trade Agreement between Japan and the European Union were officially launched in March of 2013. The impact of this eventual agreement has far reaching benefits for the pharmaceutical industry as Japan seeks to enhance the sustainability and competitiveness of its welfare system by increasing foreign investment and partnerships.
Japanese Pharmaceutical Market Overview
Japan, one of the highest per capita spending countries on medicines in the world, will reach a value of US $166 bn by 2023. The Japanese pharmaceutical is Asia's biggest pharmaceutical market, worth US $108.2 bn in 2014. This represents over 11% of the global drug market with a Compound Annual Growth Rate of 3.9% between 2013 and 2023. Looking at the various sectors, slow generics contribute to the use of patented drugs and the liberalisation of the over-the-counter drug sector will also boost pharmaceutical sales.
It has largely been defined by strong brand domination and weak generics share where traditional legislation has provided an environment for domestic firms to thrive in a market with minimal competition. Because a majority of Japan's approved medications are developed overseas, sales rather than drug development defines market behaviour and makes pricing competition the main driver for profitability.
Recently, as Japan's population ages and threatens to increase healthcare expenditures for nursing care and age related diseases, the Japanese government has been updating legislation to include increasing the market share for generics. This is good news for generics manufacturers looking to penetrate the huge market, though the government will keep generics pricing well above the US and European levels of 7 – 9% of predecessors' prices at 60 – 70%.
It is expected that the new legislation will influence the market in several areas, such as foreign investment and market entry, by increasing the importance of unique innovations and support services industries, e.g., CMOs and CROs. The BRIC economies will be the greatest competitors to generics manufacturing in the Japanese market.
As a backdrop to the current situation, in March 2013, the EU and Japan officially launched negotiations for a bilateral Free Trade Agreement with the objective of creating a level playing field between the two trading blocs. This would involve the elimination of EU duties and non-tariff barriers in Japan as well as a further opening of the Japanese public procurement market. For the pharmaceutical market this initiative would include ways of identifying policy measures to enhance the sustainability and competitiveness of the Japanese welfare system.
New drug development
In July 2014, Japan has joined the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co‐operation Scheme (PIC/S). This enables overseas suppliers to synchronise with Japanese pharmaceutical manufacturers regarding manufacturing and quality control. In addition the accession makes Japan's pharmaceutical industry more internationalized and open, and makes it even easier for foreign suppliers to enter the Japanese market.
Generic sector
Following the Japanese government's measures to reduce health expenditure, the volume of generic drugs in Japan is expected to increase over 60% by 2018. The total generics market in Japan is predicted to be worth US$12.3 billion by 2015. As the use of generic drugs in Japan continues to expand, Japanese pharmaceutical manufacturers are urgently seeking to secure new and reliable suppliers of price-competitive pharmaceutical ingredients.
Who Visits?
Pharma Sources Insight July 2025
